AU2020344214B2 - Antibiotic combination therapies - Google Patents

Antibiotic combination therapies

Info

Publication number
AU2020344214B2
AU2020344214B2 AU2020344214A AU2020344214A AU2020344214B2 AU 2020344214 B2 AU2020344214 B2 AU 2020344214B2 AU 2020344214 A AU2020344214 A AU 2020344214A AU 2020344214 A AU2020344214 A AU 2020344214A AU 2020344214 B2 AU2020344214 B2 AU 2020344214B2
Authority
AU
Australia
Prior art keywords
rifabutin
baumannii
antibiotic
colistin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020344214A
Other languages
English (en)
Other versions
AU2020344214A1 (en
Inventor
Glenn E. Dale
Marc Gitzinger
Christian Kemmer
Sergio Lociuro
Vincent Trebosc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioversys AG
Original Assignee
Bioversys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioversys AG filed Critical Bioversys AG
Publication of AU2020344214A1 publication Critical patent/AU2020344214A1/en
Application granted granted Critical
Publication of AU2020344214B2 publication Critical patent/AU2020344214B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020344214A 2019-09-12 2020-08-03 Antibiotic combination therapies Active AU2020344214B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US62/899,257 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US62/902,019 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US62/941,160 2019-11-27
US202062977659P 2020-02-17 2020-02-17
US62/977,659 2020-02-17
PCT/IB2020/000645 WO2021048610A1 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Publications (2)

Publication Number Publication Date
AU2020344214A1 AU2020344214A1 (en) 2022-04-21
AU2020344214B2 true AU2020344214B2 (en) 2026-01-22

Family

ID=72432957

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020344214A Active AU2020344214B2 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies
AU2020347536A Active AU2020347536B2 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020347536A Active AU2020347536B2 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions

Country Status (17)

Country Link
US (6) US11207305B2 (https=)
EP (3) EP4028001B1 (https=)
JP (4) JP7769605B2 (https=)
KR (1) KR20220103698A (https=)
CN (3) CN115052597B (https=)
AU (2) AU2020344214B2 (https=)
BR (2) BR112022004672A2 (https=)
CA (2) CA3154317A1 (https=)
ES (1) ES2982067T3 (https=)
HR (1) HRP20240818T1 (https=)
HU (1) HUE066936T2 (https=)
MX (1) MX2022003077A (https=)
PH (1) PH12022550610A1 (https=)
PL (1) PL4028001T3 (https=)
RS (1) RS65681B1 (https=)
SM (1) SMT202400250T1 (https=)
WO (2) WO2021048610A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) * 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN101362067A (zh) * 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
PT2247291T (pt) * 2008-02-08 2019-02-01 Red Hill Biopharma Ltd Métodos e composições para tratamento de doença inflamatória do intestino
MY158809A (en) 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
US10064858B2 (en) * 2011-01-31 2018-09-04 The United States Of America, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
CN102178604B (zh) 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
RU2472512C1 (ru) * 2011-12-06 2013-01-20 Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" Противотуберкулезная композиция и способ ее получения
WO2016013986A1 (en) * 2014-07-25 2016-01-28 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
CN107148479A (zh) * 2014-09-04 2017-09-08 赛拉诺斯股份有限公司 病原体和抗微生物剂抗性检测
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
EP3291798A4 (en) * 2015-05-04 2019-01-16 Gufic Biosciences Limited FREEZE-DRIED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND METHOD FOR THE PRODUCTION THEREOF
JP7072898B2 (ja) * 2016-08-16 2022-05-23 ユニバーシティ オブ ロチェスター ポリミキシンｂ／トリメトプリム系の治療薬を含有する医薬組成物
JP2020506236A (ja) 2017-02-07 2020-02-27 エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ 長期間持続するオートファジー誘発のための同位体増強アンブロキソール
US11701346B2 (en) * 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHROMY, B. A. et al. "Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant Acinetobacter baumannii and select agent microorganisms" Future Microbiology (2012) vol. 7, no. 8, pages 1001-1020 *
CORBETT, D. et al. "Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741" Antimicrobial Agents and Chemotherapy (August 2017) col. 61, no. 8, e00200-17 (10 pages) *
CRAIG R. MACNAIR ET AL: "Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics", NATURE COMMUNICATIONS, vol. 9, no. 1, 31 January 2018, 8 pages *
GIANNOULI, M. et al. 'Molecular Epidemiology and Mechanisms of Rifampicin Resistance In isolates from Italy', Journal of Antimicrobial Agents, vol. 36, No. 1, 2011, 58-63. *
LIM TZE-PENG ET AL: "In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore", THE JOURNAL OF ANTIBIOTICS, vol. 62, no. 12, 30 October 2009, pages 675-679 *
SAISHO, Y et al "Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects" ANTIMICROBIAL AGENTS & CHEMOTHERAPY vol. 62 no. 3 8 Jan 2018, e02163-17, 12 pages *
VAARA, M. et al. Antimicrobial Agents and Chemotherapy (August 2010) vol. 54, no. 8, pages 3341-3346 *
WEI SUN ET AL: "Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria", EMERGING MICROBES & INFECTIONS, vol. 5, no. 1, 9 November 2016, pages 1-11 *
YANG YU ET AL: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 74, 20 October 2018, pages 87-95 *
ZURAWSKI, D. V. et al. Antimicrobial Agents and Chemotherapy (December 2017) vol. 61, no. 12, e01239-17 (6 pages) *

Also Published As

Publication number Publication date
HRP20240818T1 (hr) 2024-10-11
EP4028001B1 (en) 2024-04-10
WO2021048610A1 (en) 2021-03-18
AU2020347536A1 (en) 2022-04-14
JP2026016690A (ja) 2026-02-03
KR20220103698A (ko) 2022-07-22
US20250281469A1 (en) 2025-09-11
PL4028001T3 (pl) 2024-07-22
CN115052597B (zh) 2025-07-08
AU2020344214A1 (en) 2022-04-21
US11833139B2 (en) 2023-12-05
CN120860031A (zh) 2025-10-31
JP2022548252A (ja) 2022-11-17
US20220184048A1 (en) 2022-06-16
BR112022004672A2 (pt) 2022-06-07
EP4028001C0 (en) 2024-04-10
US11351158B2 (en) 2022-06-07
CN114980889A (zh) 2022-08-30
ES2982067T3 (es) 2024-10-14
WO2021048611A1 (en) 2021-03-18
JP2025176113A (ja) 2025-12-03
BR112022004645A2 (pt) 2022-06-21
EP4028000A1 (en) 2022-07-20
SMT202400250T1 (it) 2024-07-09
AU2020347536B2 (en) 2025-09-25
JP7804570B2 (ja) 2026-01-22
MX2022003077A (es) 2022-07-11
JP7769605B2 (ja) 2025-11-13
US11207305B2 (en) 2021-12-28
CA3154317A1 (en) 2021-03-18
RS65681B1 (sr) 2024-07-31
US20230132691A1 (en) 2023-05-04
US11766425B2 (en) 2023-09-26
US12257241B2 (en) 2025-03-25
CN115052597A (zh) 2022-09-13
US20210077472A1 (en) 2021-03-18
EP4420673A2 (en) 2024-08-28
CA3154129A1 (en) 2021-03-18
US20210077471A1 (en) 2021-03-18
JP2022551228A (ja) 2022-12-08
EP4420673A3 (en) 2024-11-06
HUE066936T2 (hu) 2024-09-28
PH12022550610A1 (en) 2023-03-13
US20240041845A1 (en) 2024-02-08
EP4028001A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
JP5782615B2 (ja) オリタバンシンの単回用量を用いる治療の方法
US12370184B2 (en) Antibiotic combination therapies
JP2025176113A (ja) 抗生物質併用療法
Metallidis et al. Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty
EP3919059B1 (en) Composition for treating carbapenem antibiotic-resistant acinetobacter baumannii infection
EP2714034B1 (en) Compositions comprising cefepime and tazobactam
US20230364065A1 (en) Antibiotic combination therapies
Sheagren Staphylococci
US20110281839A1 (en) Combination therapy for the treatment of bacterial infections
Lindsay et al. 1354. Novel formulation suba-itraconazole in fed and fasted healthy volunteers: expanding the clinical utility of the established mold active agent
Inoshita et al. A randomized prospective study of oral levofloxacin vs intravenous flomoxef prophylaxis in postoperative infection after endoscopic sinus surgery
US20190388437A1 (en) Compositions and methods for treating bone and joint infections
Nord Use of newer quinolones for the treatment of intraabdominal infections: Focus on clinafloxacin
Peerbooms et al. Comparative activities of five antimicrobial agents in experimental Proteus pyelonephritis in mice
US20020037890A1 (en) Dalfopristine/quinupristine combinations with cefpirome